Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.

Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...

After two consecutive years of 20%-plus gains, the S&P 500 kicked off 2025 with a solid January performance. Investors are hoping the S&P 500 can continue to grind higher and maintain its ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...

Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...

Akero Therapeutics (NASDAQ:AKRO – Get Free Report) had its target price raised by HC Wainwright from $50.00 to $72.00 in a ...

Akero Therapeutics has revealed preliminary topline week 96 outcomes from its Phase IIb SYMMETRY study of efruxifermin (EFX) ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...